Back to results
US 11,827,910 B2Granted
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
AssigneesPresident and Fellows of Harvard College, The Board of Trustees of the Leland Stanford Junior University
InventorsQuan Lu, Qiyu Wang, Stanley N. Cohen
Life of this patent
Estimating the term…
Abstract
Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.
Claims23
A Cas9 fusion protein comprising:
- a Cas9 protein or a Cas9 protein variant, wherein the Cas9 protein variant comprises an amino acid sequence that is at least about 70% identical to any one of SEQ ID NOs:
- 2, 4, and 5, and
- a WW domain or a WW domain variant, wherein the WW domain or the WW domain variant comprises two basic residues at the C-terminus and is at least a 30 amino acid domain.
Dependencies are inferred from the claim text.